Paper Details

  1. Home
  2. Paper Details

Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.

Author: BaschEthan, BevansKatherine B, Brookman-MaySabine D, CellaDavid, De PorrePeter, DibajShiva, GraffJulie N, HadaschikBoris, LiSusan, OudardStéphane, SaadFred, SmallEric J, SmithMatthew R, TrudeauJeremiah J, UemuraHiroji

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated health-related quality of life (HRQoL) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving apalutamide or placebo in the SPARTAN trial. HRQoL was maintained in patients receiving apalutamide, but declined in patients receiving placebo. Apalutamide did not worsen patient-reported fatigue and was well tolerated. These findings, along with previous reports of improved survival and time to metastases, support the use of apalutamide for nmCRPC.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In SPARTAN, apalutamide improved metastasis-free and overall survival for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) with a prostate-specific antigen doubling time of ≤10 mo. OBJECTIVE: We evaluated health-related quality of life (HRQoL) at the final analy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.euf.2021.08.005

データ提供：米国国立医学図書館（NLM）

Apalutamide's Impact on Health-Related Quality of Life in Patients with Nonmetastatic Castration-resistant Prostate Cancer

The study delves into the [health-related quality of life (HRQoL)] of men diagnosed with [nonmetastatic castration-resistant prostate cancer (nmCRPC)]. It's a bit like a desert oasis, where research helps us understand the impact of [apalutamide] on men's well-being. The study analyzed data from the SPARTAN trial, which compared [apalutamide] to a placebo in patients receiving [androgen deprivation therapy (ADT)]. The results revealed that apalutamide significantly preserved HRQoL in these patients, while the placebo group experienced a decline in HRQoL over time. This implies that apalutamide not only improves survival but also contributes to a better quality of life for men with nmCRPC.

Apalutamide as a Potential Lifeline in the Desert of Prostate Cancer

The study highlights the significant positive impact of apalutamide on the HRQoL of men with nmCRPC. The fact that apalutamide preserves HRQoL, while placebo-treated patients experience a decline in HRQoL, suggests that apalutamide could serve as a valuable lifeline in the vast desert of prostate cancer. It provides not only a chance to extend life but also to improve the quality of life during that extension.

Hope and Quality of Life for Men with Prostate Cancer

This research provides hope for men diagnosed with nmCRPC. Apalutamide demonstrates the potential to not only increase survival but also to preserve and even enhance quality of life. It's a testament to the ongoing efforts to find more effective and humane treatments for this challenging disease. While we must remain vigilant in understanding the long-term effects, this study serves as a beacon of hope in the desert of prostate cancer.

Dr.Camel's Conclusion

The SPARTAN study provides compelling evidence for the positive impact of apalutamide on the health-related quality of life of men with nmCRPC. These findings emphasize the importance of considering HRQoL alongside survival benefits when evaluating treatment options for prostate cancer.
Date :
  1. Date Completed 2022-10-10
  2. Date Revised 2022-11-30
Further Info :

Pubmed ID

34479838

DOI: Digital Object Identifier

10.1016/j.euf.2021.08.005

Related Literature

Article Analysis
・Side Effects of apalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.